A Prospective Observational Study of Osimertinib for Chemo-Naive Elderly Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

References

• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase 3 trial. Lancet Oncol. 2010;11(2):121–128. doi:10.1016/S1470-2045(09)70364-X20022809
   PubMed Web of Science ®Google Scholar
• Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi:10.1016/S1470-2045(11)70393-X22285168
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi:10.1016/S1470-2045(11)70184-X21783417
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of Afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334. doi:10.1200/JCO.2012.44.280623816960
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. doi:10.1016/S1470-2045(13)70604-124439929
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466. doi:10.1016/S1470-2045(17)30608-328958502
   PubMed Web of Science ®Google Scholar
• Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125. doi:10.1056/NEJMoa171313729151359
   PubMed Web of Science ®Google Scholar
• Barta JA, Zinner RG, Unger M. Lung cancer in the older patient. Clin Geriatr Med. 2017;33:563–577. doi:10.1016/j.cger.2017.06.00828991651
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27. doi:10.1158/1055-9965.EPI-15-057826667886
   PubMed Web of Science ®Google Scholar
• Maemondo M, Minegishi Y, Inoue A, et al. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 2012;7(9):1417–1422. doi:10.1097/JTO.0b013e318260de8b22895139
   PubMed Web of Science ®Google Scholar
• Fujita S, Katakami N, Masago K, et al. Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial. BMC Cancer. 2012;12:185. doi:10.1186/1471-2407-12-18522613958
   PubMed Web of Science ®Google Scholar
• Takahashi K, Saito H, Hasegawa Y, et al. First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: central Japan lung study group 0901. Cancer Chemother Pharmacol. 2014;74(4):721–727. doi:10.1007/s00280-014-2548-z25087097
   PubMed Web of Science ®Google Scholar
• Uruga H, Kishi K, Fujii T, et al. Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med. 2010;49(2):103–107. doi:10.2169/internalmedicine.49.253120075572
   PubMed Web of Science ®Google Scholar
• Tateishi K, Ichiyama T, Hirai K, et al. Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano lung cancer research group study. Med Oncol. 2013;30(1):450. doi:10.1007/s12032-012-0450-223315220
   PubMed Web of Science ®Google Scholar
• Kuwako T, Imai H, Masuda T, et al. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol. 2015;76(4):761–769. doi:10.1007/s00280-015-2841-526254024
   PubMed Web of Science ®Google Scholar
• Morikawa N, Minegishi Y, Inoue A, et al. First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan study group studies. Expert Opin Pharmacother. 2015;16(4):465–472. doi:10.1517/14656566.2015.100239625597331
   PubMed Web of Science ®Google Scholar
• Inoue Y, Inui N, Asada K, et al. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations. Cancer Chemother Pharmacol. 2015;76(1):155–161. doi:10.1007/s00280-015-2784-x26003540
   PubMed Web of Science ®Google Scholar
• Imai H, Kaira K, Suzuki K, et al. A phase II study of Afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. Lung Cancer. 2018;126:41–47. doi:10.1016/j.lungcan.2018.10.01430527191
   PubMed Web of Science ®Google Scholar
• Minegishi Y, Yamaguchi O, Sugawara S, et al. A phase II study of first-line Afatinib for patients aged 75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. BMC Cancer. 2021;21(1):208. doi:10.1186/s12885-021-07861-133648453
   PubMed Web of Science ®Google Scholar
• Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220–241. doi:10.3322/caac.2114922700443
   PubMed Web of Science ®Google Scholar
• Ohe Y, Imamura F, Nogami N, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J Clin Oncol. 2019;49:29–36. doi:10.1093/jjco/hyy17930508196
   PubMed Web of Science ®Google Scholar
• Gemma A, Kusumoto M, Sakai F, et al. Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with Osimertinib in Japan. J Thorac Oncol. 2020;15(12):1893–1906. doi:10.1016/j.jtho.2020.08.02532927121
   PubMed Web of Science ®Google Scholar
• Okuma Y, Hosomi Y, Nagamata M, et al. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status. Anticancer Res. 2013;33(11):5057–5064.24222150
   PubMed Web of Science ®Google Scholar
• Wu CE, Chang CF, Huang CY, et al. Feasibility and effectiveness of Afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study. BMC Cancer. 2021;21(1):859. doi:10.1186/s12885-021-08587-w34315431
   PubMed Web of Science ®Google Scholar
• Yang JC, Wu Y, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16(2):141–151. doi:10.1016/S1470-2045(14)71173-825589191
   PubMed Web of Science ®Google Scholar
• Igawa S, Ryuge S, Ichinoe M, et al. Impact of EGFR-tyrosine kinase inhibitors on postoperative recurrent non-small-cell lung cancer harboring EGFR mutations. Oncol Res Treat. 2017;40(1–2):7–13. doi:10.1159/00045514728118631
   PubMed Web of Science ®Google Scholar
• Park S, Holmes-Tisch AJ, Cho EY, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol. 2009;4(7):809–815. doi:10.1097/JTO.0b013e3181a94af419487967
   PubMed Web of Science ®Google Scholar
• Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum Pathol. 2010;41(1):94–102. doi:10.1016/j.humpath.2009.06.01919740513
   PubMed Web of Science ®Google Scholar
• Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008;99(5):929–935. doi:10.1111/j.1349-7006.2008.00782.x18325048
   PubMed Web of Science ®Google Scholar
• Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13(4):e178–e185. doi:10.1016/S1470-2045(11)70335-722469128
   PubMed Web of Science ®Google Scholar
• Park JH, Kim TM, Keam B, et al. Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib. Clin Lung Cancer. 2013;14(4):383–389. doi:10.1016/j.cllc.2012.10.00723313171
   PubMed Web of Science ®Google Scholar
• Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012;39(1):27–38. doi:10.1007/s00259-011-1934-621946983
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Yamada T, Okura N, et al. Clinical characteristics of osimertinib responder in non-small cell lung cancer patients with EGFR T790M mutation. Cancers. 2019;11(3):365. doi:10.3390/cancers11030365
   PubMed Web of Science ®Google Scholar
• Kuo CS, Huang C, Liu C, et al. Prior EGFR-TKI treatment in EGFR mutated NSCLC affects the allele frequency fraction of acquired T790M and the subsequent efficacy of Osimertinib. Target Oncol. 2019;14(4):433–440. doi:10.1007/s11523-019-00657-131346928
   PubMed Web of Science ®Google Scholar
• Su PL, Yang SC, Chen YL, et al. Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment. Cancer Med. 2019;8(13):5939–5947. doi:10.1002/cam4.248531433117
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med. 2017;376(7):629–640. doi:10.1056/NEJMoa161267427959700
   PubMed Web of Science ®Google Scholar
• Yang JCH, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–1296. doi:10.1200/JCO.2016.70.322328221867
   PubMed Web of Science ®Google Scholar